Avila Therapeutics

Avila Therapeutics, Inc. designs and develops covalent drugs for viral infections, cancer, and autoimmune diseases. It provides AVL-181, a small molecule hepatitis C virus protease inhibitor. Avila Therapeutics, Inc. has established a strategic alliance with Sanofi-Aventis. The company was founded in 2006 and is headquartered in Waltham, Massachusetts. As of March 7, 2012, Avila Therapeutics, Inc. operates as a subsidiary of Celgene Corporation.